可解释的等级机器学习方法,用于从轻度认知障碍转化为阿尔茨海默病的多式预测
Soheil Zarei1, Mohsen Saffar2, Reza Shalbaf1
1Institute for Cognitive Science Studies, Tehran, Iran.
Physical and engineering sciences in medicine
|August 11, 2025
概括
这项研究开发了一种可解释的机器学习模型,用于预测阿尔茨海默病 (AD) 从轻度认知障碍 (MCI) 的进展. 该模型准确地识别了关键预测因素,如海马体积和记忆回忆,有助于早期诊断.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 生物医学信息学 生物医学信息学
背景情况:
- 阿尔茨海默病 (AD) 的诊断和干预受到神经退行症复杂性的挑战.
- 预测AD进展的预测模型往往缺乏临床透明度,因为它们的"黑子"性质.
- 早期识别轻度认知障碍 (MCI) 进展为AD对于及时治疗至关重要.
研究的目的:
- 开发一个先进的,可解释的机器学习 (ML) 框架,用于预测MCI转换为AD.
- 整合分层特征选择和可解释性方法 (SHAP) 进行临床解释性.
- 确定AD进展的关键预测特征和生物标志物.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划 (ADNI) 580名参与者的基线数据.
- 采用分层特征选择,结合统计过和ML改进,以确定顶级预测器.
- 应用SHAP (夏普利添加式扩展) 分析对可解释的随机森林分类器进行特征贡献评估.
主要成果:
- 神经心理测试组为MCI转化为AD提供了最具预测性的特征.
- 层次特征选择确定了八个高度信息化的变量.
- 可解释的随机森林模型实现了83.79%的准确性,其中海马体积,LDELTOTAL和FAQ分数作为主要驱动因素.
结论:
- 开发的ML框架有效地预测了AD从MCI的进展,具有高准确性和透明度.
- 基于SHAP的可解释性将模型见解与已知的AD生物标志物结合起来,增强了临床信任.
- 这种方法将预测模型转化为临床可行的工具,用于早期AD诊断和患者分层.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.3K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.0K
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
